AIORG-W028 Practitioner & vendor artifacts AI × management and organizations

Moderna builds organization-wide AI adoption and custom assistants with OpenAI

Also recorded as: OpenAI-Moderna enterprise case · mChat and custom GPT case

vendor focal organization case page

Recorded claims
2
coded from the inspected source
Evidence classes
1
first-party-organization
Recorded limitations
5
stated, never hidden

From the hash-bound evidence releases

Recorded claims

Each claim states what the inspected source says, at the recorded location—bounded by its scope and graded by its confidence. Nothing here is a synthesis across works.

The case reports that more than 80% of employees used Moderna's earlier mChat, employees created more than 750 custom GPTs, about 40% of weekly active users had built a GPT, and users averaged about 120 conversations per week.

confidence: medium-high for reported values; low for causal effects first-party-organization apw-r0-seed

Scope: Moderna's reported internal use; frequency is not productivity, safety, or business value.

Moderna's described method asks teams to review every process for possible redesign, while the Dose ID example positions AI as an assistant to a clinical team and explicitly retains human scientific and clinical judgment.

confidence: medium-high for described practice first-party-organization apw-r0-seed

Scope: Reported internal operating practices and one clinical-assistant example.

Structured relationships

In-corpus citations

Only source-supplied cites relationships whose two endpoints are admitted are shown. Invocation evidence remains a separate relationship.

Cites (0)

No in-corpus outgoing citation is available in the current enrichment coverage.

Cited by (0)

No in-corpus incoming citation is available in the current enrichment coverage.

Boundaries

Limitations & independence

Recorded at coding time, carried with the work forever. A claim without its limits is not evidence.

Recorded limitations

  • Showcase-case selection
  • Usage is not outcome quality
  • No control group
  • Clinical/regulatory decisions remain domain-specific
  • Vendor/customer source

Source independence

Joint vendor/focal-organization case; reported adoption and workflow metrics are not independently audited.